Based on the information gathered about TREM2, its protein interactions, and pathways, I'll now generate novel therapeutic hypotheses for targeting TREM2 in Alzheimer's disease following the INVOKE-2 failure:
## Novel Therapeutic Hypotheses for TREM2 in Alzheimer's Disease
### Hypothesis 1: TYROBP-SYK Pathway Enhancement
**Title:** Selective TYROBP stabilization to bypass TREM2 ectodomain loss
**Description:** Given TREM2's obligate partnership with TYROBP (DAP12) for signaling, developing small molecule stabilizers of the TYROBP-SYK complex could maintain downstream neuroprotective signaling even when TREM2 surface expression is reduced. This approach targets the intracellular cascade rather than the problematic extracellular domain that likely contributed to INVOKE-2's failure.
**Target gene/protein:** TYROBP, SYK
**Supporting evidence:** STRING analysis reveals extremely high confidence interactions (score: 0.998) between TREM2-TYROBP and TYROBP-SYK. Reactome pathway analysis confirms DAP12 (TYROBP) interactions and signaling as core TREM2 pathways. The failure of agonistic approaches suggests targeting downstream effectors may be more viable.
**Confidence:** 0.75
### Hypothesis 2: APOE-TREM2 Synergistic Modulation
**Title:** Dual APOE mimetic and TREM2 co-activator therapy
**Description:** The exceptionally strong APOE-TREM2 interaction (score: 0.986) suggests these proteins function in concert for microglial lipid metabolism and amyloid clearance. A combination therapy using APOE mimetics alongside selective TREM2 intracellular domain activators could restore the functional APOE-TREM2 axis without relying on problematic ectodomain targeting.
**Target gene/protein:** APOE, TREM2
**Supporting evidence:** STRING database shows the highest confidence APOE-TREM2 interaction among all identified partners. Literature indicates both proteins are critical for microglial function in AD (PMIDs: 40050704, 39218078). CLU also shows strong interactions with both proteins, suggesting a coordinated lipid-handling network.
**Confidence:** 0.70
### Hypothesis 3: SIRPA-Mediated Microglial Disinhibition
**Title:** SIRPA antagonism to enhance TREM2-independent microglial activation
**Description:** SIRPA (CD47 receptor) interactions with TREM2 pathway components suggest it may act as a brake on microglial activation. Selective SIRPA antagonists could remove inhibitory signals and promote beneficial microglial phenotypes through parallel pathways, compensating for TREM2 dysfunction while avoiding direct TREM2 targeting complications.
**Target gene/protein:** SIRPA
**Supporting evidence:** STRING analysis reveals SIRPA interactions with multiple TREM2 pathway components (TYROBP, SIRPG, SYK, TREM2 itself). SIRPA is known as an inhibitory receptor that prevents phagocytosis when bound to CD47, suggesting its antagonism could enhance clearance functions.
**Confidence:** 0.65
### Hypothesis 4: Soluble TREM2 Sequestration and Recycling
**Title:** Engineered TREM2 scavenger proteins to restore membrane-bound function
**Description:** Rather than stimulating TREM2, develop engineered proteins that capture shed soluble TREM2 and facilitate its re-membrane insertion or prevent its proteolytic cleavage. This addresses the fundamental problem of TREM2 shedding that may limit surface availability for therapeutic targeting.
**Target gene/protein:** TREM2
**Supporting evidence:** The failure of agonistic approaches suggests that TREM2 bioavailability, not just activity, may be the issue. Literature shows soluble TREM2 levels are altered in AD (PMIDs: 41654144, 39218078), indicating shedding as a key pathological mechanism.
**Confidence:** 0.60
### Hypothesis 5: FCER1G-Mediated Alternative Immune Signaling
**Title:** FCER1G co-activation to create TREM2-bypass immune signaling
**Description:** FCER1G shows strong interactions with TREM2 (score: 0.977) and SYK (score: 0.999), suggesting it could serve as an alternative immune receptor signaling pathway. Selective FCER1G agonists could activate similar downstream cascades to TREM2 while avoiding the problematic aspects of direct TREM2 targeting.
**Target gene/protein:** FCER1G
**Supporting evidence:** STRING analysis reveals FCER1G as a high-confidence TREM2 partner with shared SYK signaling. FCER1G is an immunoreceptor gamma chain that could potentially substitute for compromised TREM2 signaling in maintaining microglial function.
**Confidence:** 0.55
### Hypothesis 6: Temporal TREM2 Pathway Modulation
**Title:** Stage-specific TREM2 pathway targeting based on disease progression
**Description:** The INVOKE-2 failure may reflect inappropriate timing of intervention. Develop biomarker-guided approaches that enhance TREM2 signaling early in disease (when microglia need activation) but modulate it differently in late stages (when over-activation may be harmful). This requires stage-specific compounds with opposing effects.
**Target gene/protein:** TREM2, TYROBP
**Supporting evidence:** Literature suggests complex, stage-dependent roles of neuroinflammation in AD (PMIDs: 36768235, 32296418). The failure of a single approach may reflect this complexity requiring temporal precision in therapeutic intervention.
**Confidence:** 0.80
### Hypothesis 7: Multi-Target Microglial Metabolic Reprogramming
**Title:** Combinatorial lipid metabolism and immune signaling restoration
**Description:** Since TREM2, APOE, and CLU all interact strongly and regulate lipid metabolism, develop combination therapies targeting multiple nodes simultaneously: APOE enhancement, CLU stabilization, plus selective metabolic reprogramming of microglia toward anti-inflammatory phenotypes. This systems-level approach addresses the network disruption rather than single targets.
**Target gene/protein:** TREM2, APOE, CLU
**Supporting evidence:** STRING analysis shows a tight network between TREM2 (0.986), APOE, and CLU (0.991 APOE-CLU interaction). Literature emphasizes metabolic dysfunction in AD microglia (PMIDs: 35741054, 38986845). Multi-target approaches may overcome single-target failures.
**Confidence:** 0.85